DeepMed Research

Tipranavir

Generic Name: Tipranavir

Brand Names: Aptivus

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₃₃F_₃N_₂O_₅S

CAS Number: 174484-41-4

Unique Ingredient Identifier: ZZT404XD09

Background: Tipranavir is a sulfonamide-containing dyhydropyrone and a nonpeptidic protease inhibitor that targets the HIV protease. Tipranavir and ritonavir are coadministered to treat HIV.

Indication: For combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors.

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Clarithromycin
Other: High-Fat Test Meal

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02251769

The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Loperamide

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02251119

Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir oral solution
Drug: Tipranavir capsules
Drug: Ritonavir soft gel capsules
Drug: Ritonavir oral solution
Other: High fat breakfast

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02251158

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir medium dose
Drug: Tipranavir high dose
Drug: Tipranavir low dose
Drug: Ritonavir low dose
Drug: Ritonavir high dose

First Posted Date: 2014-09-29

Last Posted Date: 2014-09-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 208

Registration Number: NCT02251223

Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir (TPV) low
Drug: Tipranavir (TPV) high
Drug: Ritonavir (RTV) low
Drug: Ritonavir (RTV) high
Drug: Zidovudine

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT02249416

Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Tipranavir (TPV)
Drug: Ritonavir (r)

First Posted Date: 2014-09-25

Last Posted Date: 2025-01-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 24

Registration Number: NCT02249442

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Tipranavir (TPV)
Drug: Ritonavir (RTV)
Drug: Delavirdine (DLV)
Drug: Zidovudine (ZDV)
Drug: Lamivudine (3TC)
Drug: Stavudine (d4T)

First Posted Date: 2014-09-25

Last Posted Date: 2014-09-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 18

Registration Number: NCT02249130

Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Methadone

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT02245451

Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Tipranavir high dose
Drug: Tipranavir low dose
Drug: Ritonavir low dose
Drug: Ritonavir high dose
Drug: Norethindrone-Ethinyl Estradiol

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 52

Registration Number: NCT02245438

Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Atorvastatin
Drug: Maalox

First Posted Date: 2014-09-19

Last Posted Date: 2014-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT02245269

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy